1Klein R,Klein BE,Linton KL.Prevalence of age-related maculopa-thy.The Beaver Dam Eye Study[J].Ophthalmology,1992,99(6):933-943.
2Jermak CM,Dellacroce JT,Heffez J,et al.Triamcinolone acetonide in ocular therapeutics[J].Surv Ophthalmol,2007,52(5):503-522.
3Penfold PL,Gyory J,Hunyor A,et al.Effects of triamcinolone ace-tonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration[J].Clin Ex-periment Ophthalmol,2001,29(3):188-192.
5Christen WG,Glynn RJ,Chew EY,et al.Low-dose aspirin and medi-cal record-confirmed age-related macular degeneration in a random-ized trial of women[J].Ophthalmology,2009,116(12):2386-2392.
6Yoshinaga N,Arimura N,Otsuka H,et al.NSAIDs inhibit neovascu-larization of choroid through HO-1-dependent pathway[J].Lab In-vest,2011,91(9):1277-1290.
7Augustin A.Anecortave acetate in the treatment of age-related macu-lar degeneration[J].Clin Interv Aging,2006,1(3):237-246.
8Aggermann T,Haas PS.Binder.Anecortave acetate for fibrotic le-sions with presence of residual peripheral activity in age-related macular degeneration[J].Ann Ophthalmol(Skokie),2008,40(1):28-30.
9Grisanti S.Bevacizumab:off-label use in ophthalmology[J].Indian J Ophthalmol,2007,55(6):417-420.
10Takahashi M,Kishi S.Intravitreal bevacizumab for age-related mac-ular degeneration with good visual acuity[J].Jpn J Ophthalmol,2010,54(6):565-570.
